Psoriasis and latitude: Analytic approaches and future data needs.
Hartman, Rebecca I, and Alexa B Kimball. 2017. “Psoriasis and Latitude: Analytic Approaches and Future Data Needs.”. Journal of the American Academy of Dermatology 77 (2): e59.
Search
Search results
5012 results found
Psoriasis - The Life Course Approach.
Linder, Michael Dennis, Stefano Piaserico, Matthias Augustin, Anna Belloni Fortina, Arnon D Cohen, Uwe Gieler, Gregor B E Jemec, et al. 2016. “Psoriasis - The Life Course Approach.”. Acta Dermato-Venereologica 96 (217): 102-8.
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball, A B, J Schenfeld, N A Accortt, M S Anthony, K J Rothman, and D Pariser. 2015. “Cohort Study of Malignancies and Hospitalized Infectious Events in Treated and Untreated Patients With Psoriasis and a General Population in the United States.”. The British Journal of Dermatology 173 (5): 1183-90.
Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
Golbari, N M, J M van der Walt, A Blauvelt, C Ryan, P van de Kerkhof, and A B Kimball. 2021. “Psoriasis Severity: Commonly Used Clinical Thresholds May Not Adequately Convey Patient Impact.”. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2): 417-21.
Treatment of psoriasis in pregnancy.
Flood, Kelsey S, Kevin T Savage, Martina L Porter, and Alexa B Kimball. 2020. “Treatment of Psoriasis in Pregnancy.”. Cutis 106 (2S): 15-20.
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
Strober, Bruce, Caitriona Ryan, Peter van de Kerkhof, Joelle van der Walt, Alexa B Kimball, Jonathan Barker, Andrew Blauvelt, and International Psoriasis Council Board Members and Councilors. 2020. “Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council.”. Journal of the American Academy of Dermatology 82 (1): 117-22.
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Reich, K, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, and A B Kimball. 2019. “Safety of Guselkumab in Patients With Moderate-to-Severe Psoriasis Treated through 100 Weeks: A Pooled Analysis from the Randomized VOYAGE 1 and VOYAGE 2 Studies.”. The British Journal of Dermatology 180 (5): 1039-49.
Clinical Goals and Barriers to Effective Psoriasis Care.
Strober, Bruce E, Joelle M van der Walt, April W Armstrong, Marc Bourcier, Andre E Carvalho V, Edgardo Chouela, Arnon D Cohen, et al. 2019. “Clinical Goals and Barriers to Effective Psoriasis Care.”. Dermatology and Therapy 9 (1): 5-18.
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley, R G, A B Kimball, H Nak, W Xu, B Pangallo, O O Osuntokun, N Agada, and K Reich. 2019. “Long-Term Safety Profile of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis from 11 Clinical Trials.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (2): 333-39.
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt, A, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2018. “Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials.”. The British Journal of Dermatology 179 (3): 615-22.